VERSANT™ 440 FDA Approved for HCV

go back to news archives
Siemens Healthcare has announced that its VERSANT™ 440 Molecular System has been approved for marketing by the U.S. Food and Drug Administration (FDA) for use with the VERSANT HCV RNA 3.0 assay for management of HCV-infected patients undergoing antiviral therapy. The VERSANT 440 Molecular System represents the next generation in automated viral load testing, providing laboratories with greater throughput and less hands-on time, maximizing productivity to meet the evolving needs of the clinical laboratory.

The VERSANT 440 Molecular System is a branched DNA (bDNA) system designed for flexible walk-away automation. Its single room technology and consolidated footprint allow the system the flexibility to fit anywhere in the clinical laboratory. The VERSANT 440 System streamlines workflow by integrating bar code data entry, automated reagent processing, signal amplification detection, and a Laboratory Information System interface for downloading patient work lists and results.

The VERSANT 440 Molecular System uses bDNA technology that simplifies testing by eliminating nucleic acid extraction and reducing the risk of cross-contamination. With a high level of reproducibility, VERSANT HCV 3.0 Assay allows viral load changes to be distinguished accurately, enhancing hepatitis C viral load management. The HCV RNA 3.0 Assay run on the VERSANT 440 demonstrates excellent precision across the entire reporting range and equivalent detection of all HCV RNA genotypes. CE Marked in September of 2006, the VERSANT 440 has been successfully launched throughout Europe, Africa, and parts of Asia and the Americas.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Siemens Healthcare Diagnostics View Company Information

Posted on February 19, 2008

bioMerieux 3P CONNECT fully digitalized EM solution
advertisement
Enumeration of TYMC in Water in 48 hours with Diamidex MICA Highlight
advertisement
Maximizing Efficiency With BAMS Cherwell Expert Insights
advertisement
compare products in the buyers directory
advertisement

LATEST MICROBIOLOGY NEWS

MICROBIOLOGY EVENTS

RMB LOGO

Get all the latest updates on products and services for your microbiology lab in the free weekly rapidmicrobiology newsletter - sign up now!

Contact info

  • Rapid Test Methods Ltd
  • C/O O’Mahony Donnelly Limited (Xeinadin Group), BLDG G West Cork Technology Park, Clonakilty, CORK, Ireland P85 VF62.
  • +[353] 2388 31884
  • info@rapidmicrobiology.com

Submit

rapidmicrobiology

Other sections

© 2001 - 2024 Rapid Test Methods Ltd. All rights reserved.